Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Inherited variants in multiple different genes are associated with increased risk for Alzheimer's disease (AD). In many of these genes, the inherited variants alter some aspect of the production or clearance of the neurotoxic amyloid β-peptide (Aβ). Thus missense, splice site or duplication mutants in the presenilin 1 (PS1), presenilin 2 (PS2) or the amyloid precursor protein (APP) genes, which alter the levels or shift the balance of Aβ produced, are associated with rare, highly penetrant autosomal dominant forms of Familial Alzheimer's Disease (FAD). Similarly, the more prevalent late-onset forms of AD are associated with both coding and non-coding variants in genes such as SORL1, PICALM and ABCA7 that affect the production and clearance of Aβ. This review summarises some of the recent molecular and structural work on the role of these genes and the proteins coded by them in the biology of Aβ. We also briefly outline how the emerging knowledge about the pathways involved in Aβ generation and clearance can be potentially targeted therapeutically. This article is part of Special Issue entitled "Neuronal Protein".
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 3×
“genome-wide significance in a subsequent very large meta-analysis of 74,046 individuals (Lambert et al., 2013).”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“…longitudinal assessment of presymptomatic carriers of presenilin or APP mutations have revealed that the amyloid pathology begins more than a decade before onset of symptoms, and is followed by tau misprocessing and activation of inflammatory processes (Bateman et al., 2012; Lippa et al., 1998).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“…list of genes in which common or rare variants (either in noncoding regulatory sequences or in coding sequences) are associated with small increments in risk for AD (Cruchaga et al., 2014; Guerreiro et al., 2013; Harold et al., 2009; Hoglinger et al., 2011; Lambert et al., 2013; Naj et al., 2011).”
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 4×
“Finally, the presence of extracellular misfolding protein aggregates such as amyloid oligomers and fibrils is known to activate innate immune responses via complement pathways, including complement receptor (CR1), and microglial signalling elements, such as TREM2 (see review) (Heneka et al., 2014; Schwartz and Shechte…”
BackgroundNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 1×
“While activation of innate immune responses may initially be a protective response directed at removal of these mis-folded proteins, there is increasing evidence that chronic activation of these pathways may lead to injury of neurons via the inflammasome (Heneka et al., 2013; Tan et al., 2013).”
BackgroundScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 3×
“Finally, the presence of extracellular misfolding protein aggregates such as amyloid oligomers and fibrils is known to activate innate immune responses via complement pathways, including complement receptor (CR1), and microglial signalling elements, such as TREM2 (see review) (Heneka et al., 2014; Schwartz and Shechte…”
BackgroundLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“One of these protein aggregates is composed of hyperphosphorylated tau proteins, which assemble into intraneuronal neurofibrillary tangles (NFT) (Ballatore et al., 2007; Buée et al., 2000; Goedert, 2005; Lee et al., 2001; Terry, 1963).”
BackgroundThe amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“One of these protein aggregates is composed of hyperphosphorylated tau proteins, which assemble into intraneuronal neurofibrillary tangles (NFT) (Ballatore et al., 2007; Buée et al., 2000; Goedert, 2005; Lee et al., 2001; Terry, 1963).”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 4×
“Patients with familial Alzheimer's disease (FAD) carry mutations in either the APP (Goate et al., 1991), presenilin 1 (PSEN1) (Sherrington et al., 1995) or presenilin 2 genes (PSEN2) (Rogaev et al., 1995; Finckh et al., 2000) (Fig.”
BackgroundSelf-citationRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 1×
“RAGE is increased in brain blood vessels in AD cases (Yan et al., 1996).”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 2×
“This review will focus upon the biology of the Aβ peptide.”
BackgroundNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 4×
“Similarly, both coding (rare sequence variants and a common in frame insertion) and non-coding sequence variants in the complement receptor 1 (CR1) have been associated with late-onset AD (Hazrati et al., 2012; Jun et al., 2010; Naj et al., 2011; Wyss-Coray et al., 2002).”
BackgroundSelf-citationDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 3×
“Published by Elsevier Inc a b s t r a c t a r t i c l e i n f o Article history: Received 8 January 2015 Revised 26 February 2015 Accepted 27 February 2015 Available online 4 March 2015 Keywords: Alzheimer Abeta Amyloid Tau Genetics Next generation sequencing PICALM SORL1 EPHA1 APOE APP Vaccine…”
BackgroundAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“Indeed, the literature is replete with in vitro, cellular and animal modelling studies of candidate therapeutics within these pathways (see reviews (Hampel et al., 2014; Huang and Mucke, 2012)).”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“Some FAD mutations in PS1 (Citron et al., 1997), PS2 (Scheuner et al., 1996) andAPP (Citron et al., 1992) shift Aβproduction from Aβ40 to the more aggregation-prone Aβ42.”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“As the molecular details of the nodal control points within these pathways become known in greater detail, it is likely that systems biology approaches will be able to mine useful therapeutic targets from these pathways (Rhinn et al., 2013; Santiago and Potashkin, 2014; Zhang et al., 2013).”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 2×
“Specifically there is emerging evidence to support the view that these apparently disparate observations actually reflect the presence of two different processes: 1) age-related neurodegeneration in the hippocampuswith tauopathy butwithout Aβ pathology (primary age-related tauopathy — PART); and 2) independent Aβ-asso…”
BackgroundInnate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437 · cited 2×
“…misfolding protein aggregates such as amyloid oligomers and fibrils is known to activate innate immune responses via complement pathways, including complement receptor (CR1), and microglial signalling elements, such as TREM2 (see review) (Heneka et al., 2014; Schwartz and Shechter, 2010).”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Self-citationHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“In a follow-up study the immunised group exhibited some reduction in brain Aβ load compared to the control group but failed to improve cognitive markers in the small sample studied (Holmes et al., 2008; reviewed in St George-Hyslop and Morris, 2008).”
ResultSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 2×
“An early trial with the active immunisation compound AN-1792 (Elan Pharmaceuticals) was halted after a subset of participants developed encephalitis (Orgogozo et al., 2003).”
BackgroundCitron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 3×
“Thus missense, splice site or duplication mutants in the presenilin 1 (PS1), presenilin 2 (PS2) or the amyloid precursor protein (APP) genes, which alter the levels or shift the balance of Aβ produced, are associatedwith rare, highly penetrant autosomal dominant forms of Familial Alzheimer's Disease (FAD).”
BackgroundSelf-citationA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 2×
“…et al., 2006) and Down's syndrome (Wisniewski et al., 1985)); 2) rendering APP more accessible to BACE (e.g., the APP KM670/671NL Swedish APP mutation (Haass et al., 1995)); or 3) increasing the aggregation propensity of Aβ peptides (e.g., APP E693G Arctic mutation (Nilsberth et al., 2001)).”
BackgroundThe neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 2×
“…with sorting receptors, including SORL1 determine whether the full-length APP holoprotein is redirected to the retromer compartment, or allowed to drift into the late endosomal compartment (Rogaeva et al., 2007; Bhalla et al., 2012; Lane et al., 2012; Seaman, 2012; Vardarajan et al., 2012)).”
BackgroundSelf-citationTrafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 1×
“…thus occurs 49 amino acids from the BACE cleavage site at the cytoplasmic side of the transmembrane domain (Chow et al., 2010; Fuwa et al., 2007; Haass et al., 2012; Takami et al., 2009; Tomita and Iwatsubo, 2013; Weidemann et al., 2002) Subsequently, ζ-cleavage follows at position 46 from the…”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 2×
“In 2012, a report gained wide attention describing efficient clearance of Aβ deposits in an AD mousemodel after injectionswith bexarotene, anRXRagonist approved for cancer therapy (Cramer et al., 2012).”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · cited 5×
“Although APOE's interaction with Aβ has come under some scrutiny recently, multiple groups found that APOE may compete with Aβ for LRP, rather than play the role of courier (Sagare et al., 2013; Verghese et al., 2013).”
BackgroundInfluentialTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 2×
“This review will focus upon the biology of the Aβ peptide.”
BackgroundControl of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“There exist continuing concerns about the potential effect of partial inhibition of other BACE substrates such as neuregulin (Willem et al., 2006) or subunits of voltage-gated sodium channels (Kim et al., 2007).”
BackgroundLXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683 · cited 2×
“Expression of APOE is controlled by liver X receptor (LXR) in a heterodimerwith other nuclear receptors, including retinoid X receptor (RXR) and peroxisome proliferator-activated receptor γ (PPARγ) (Laffitte et al., 2001).”
BackgroundHaass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592 · cited 1×
“…et al., 2006) and Down's syndrome (Wisniewski et al., 1985)); 2) rendering APP more accessible to BACE (e.g., the APP KM670/671NL Swedish APP mutation (Haass et al., 1995)); or 3) increasing the aggregation propensity of Aβ peptides (e.g., APP E693G Arctic mutation (Nilsberth et al., 2001)).”
BackgroundBertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511 · cited 2×
“CD33 failed to achieve genome-wide significance in a subsequent very large meta-analysis of 74,046 individuals (Lambert et al., 2013).”
BackgroundTakami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., & Ihara, Y. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2362-09.2009 · Cited by 498
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 1×
“Similarly, both coding (rare sequence variants and a common in frame insertion) and non-coding sequence variants in the complement receptor 1 (CR1) have been associated with late-onset AD (Hazrati et al., 2012; Jun et al., 2010; Naj et al., 2011; Wyss-Coray et al., 2002).”
BackgroundMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 2×
“…based on passive immunisation with recombinant anti-Aβ antibodies have all failed to produce convincing evidence for efficacy, at least under the conditions studied in these trials, even though some of them (e.g., gantenerumab–Roche) had shown promise in a phase 2 trial (Ostrowitzki et al., 2012).”
BackgroundCorrelations of synaptic and pathological markers with cognition of the elderly
Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., & Davies, P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00013-5 · Cited by 410 · cited 2×
“In the stoichiometrically predominant pathway (Ray et al., 2011), APP is initially subject to α-secretase cleavage, which can be executed by one of several members of the ADAM (a disintegrin and metalloproteinase domain) protease family, including ADAM10, ADAM17, ADAM9 and ADAM19 (Esch et al.,…”
BackgroundTHE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMERʼS DISEASE
Terry, R. D. (1963) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196310000-00005 · Cited by 403 · cited 1×
“One of these protein aggregates is composed of hyperphosphorylated tau proteins, which assemble into intraneuronal neurofibrillary tangles (NFT) (Ballatore et al., 2007; Buée et al., 2000; Goedert, 2005; Lee et al., 2001; Terry, 1963).”
BackgroundA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · cited 2×
“had to be discontinued due to toxicity (Salloway et al., 2011).”
BackgroundSystemic inflammatory cells fight off neurodegenerative disease
Schwartz, M., & Shechter, R. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.71 · Cited by 240 · cited 2×
“…misfolding protein aggregates such as amyloid oligomers and fibrils is known to activate innate immune responses via complement pathways, including complement receptor (CR1), and microglial signalling elements, such as TREM2 (see review) (Heneka et al., 2014; Schwartz and Shechter, 2010).”
BackgroundSuh, J., Choi, S. H., Romano, D. M., Gannon, M. A., Lesinski, A. N., Kim, D. Y., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.08.035 · Cited by 217 · cited 2×
“ADAM10 is the dominant αsecretase in the brain and recently two rare mutations in ADAM10 were identified which were suggested as predisposing for late-onset Alzheimer's disease (Suh et al., 2013).”
Coding mutations in SORL1 and Alzheimer disease
Vardarajan, B. N., Zhang, Y., Lee, J. H., Cheng, R., Bohm, C., Ghani, M., Reitz, C., Reyes‐Dumeyer, D., Shen, Y., Rogaeva, E., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24305 · Cited by 191 · cited 1×
“Thus variants in SORL1, PICALM, ABCA7, ADAM10 and PLD3 have both been implicated in increasing Aβ production by altering the intracellular processing of APP, and/or been shown to modulate the uptake of already produced Aβ (Cruchaga et al., 2014; Vardarajan et al., 2015) (Figs.”
BackgroundPrice, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138
Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133 · cited 2×
“While activation of innate immune responses may initially be a protective response directed at removal of these mis-folded proteins, there is increasing evidence that chronic activation of these pathways may lead to injury of neurons via the inflammasome (Heneka et al., 2013; Tan et al., 2013).”
BackgroundApoE immunoreactivity and microglial cells in Alzheimer’s disease brain
Uchihara, T., Duyckaerts, C., He, Y., Kobayashi, K., Seilhean, D., Amouyel, P., & Hauw, J.-J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11763-m · Cited by 131
Bhalla, A., Vetanovetz, C. P., Morel, E., Chamoun, Z., Di Paolo, G., & Small, S. A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.030 · Cited by 130
Tesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128
Thal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100 · cited 2×
“…on the amyloid cascade has been the development of CSF and neuroimaging biomarkers for the measurement of Aβ and tau accumulation in the brain of asymptomatic and symptomatic (Jack and Holtzman, 2013; Lleo et al., 2015; Risacher and Saykin, 2013; Thal et al., 2014; Wicklund and Petersen, 2013).”
BackgroundEffect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype
Thambisetty, M., An, Y., Nalls, M., Sojkova, J., Swaminathan, S., Zhou, Y., Singleton, A. B., Wong, D. F., Ferrucci, L., Saykin, A. J., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.015 · Cited by 90
Will anti-amyloid therapies work for Alzheimer's disease?
St George-Hyslop, P. H., & Morris, J. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61047-8 · Cited by 69
Cited by
Mouse models of Alzheimer’s disease
Esquerda-Canals, G., Montoliu-Gaya, L., Güell-Bosch, J., & Villegas, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170045 · Cited by 288
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190
“Much current therapeutic research is focused on the amyloid hypothesis and means of redressing the imbalance between production and clearance of amyloid-β (Aβ) protein that leads to peptide aggregation, neurotoxicity, and formation of neuritic plaques [5].”
BackgroundDourlen, P., Fernandez-Gomez, F. J., Dupont, C., Grenier-Boley, B., Bellenguez, C., Obriot, H., Caillierez, R., Sottejeau, Y., Chapuis, J., Bretteville, A., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.59 · Cited by 118
Adams, S. L., Tilton, K., Kozubek, J. A., Seshadri, S., & Delalle, I. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw056 · Cited by 45
Regulation of the alternative β-secretase meprin β by ADAM-mediated shedding
Scharfenberg, F., Armbrust, F., Marengo, L., Pietrzik, C., & Becker-Pauly, C. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03179-1 · Cited by 29
Metadata
- Authors
- Bohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., Schmitt-Ulms, G., Fraser, P. E., & St George-Hyslop, P. H.
- Venue
- Molecular and Cellular Neuroscience
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 66
- Issue
- Pt A
- Pages
- 3-11
- ISSN
- 1044-7431 (ISSN-L)
- OpenAlex
- W2018437537
- Cited by
- 63
- References
- 60
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.